Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer

Lack of durable response to cytotoxic chemotherapy is a major contributor to the dismal outcomes seen in pancreatic ductal adenocarcinoma (PDAC). Extensive tumor desmoplasia and poor vascular supply are two predominant characteristics which hinder the delivery of chemotherapeutic drugs into PDAC tum...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular cancer research Vol. 18; no. 4; p. 623
Main Authors:	Dosch, Austin R, Dai, Xizi, Reyzer, Michelle L, Mehra, Siddharth, Srinivasan, Supriya, Willobee, Brent A, Kwon, Deukwoo, Kashikar, Nilesh, Caprioli, Richard, Merchant, Nipun B, Nagathihalli, Nagaraj S
Format:	Journal Article
Language:	English
Published:	United States 01.04.2020
Subjects:	Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Dasatinib - administration & dosage Dasatinib - pharmacology Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Disease Models, Animal ErbB Receptors - antagonists & inhibitors ErbB Receptors - metabolism Erlotinib Hydrochloride - administration & dosage Erlotinib Hydrochloride - pharmacology Female Humans Mice Mice, Nude Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Protein Kinase Inhibitors - pharmacology Signal Transduction - drug effects src-Family Kinases - antagonists & inhibitors src-Family Kinases - metabolism STAT3 Transcription Factor - antagonists & inhibitors STAT3 Transcription Factor - metabolism Stromal Cells - drug effects Stromal Cells - metabolism Stromal Cells - pathology Survival Analysis Xenograft Model Antitumor Assays
ISSN:	1557-3125, 1557-3125
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!